These findings demonstrate that the activation of Nrf2 exacerbates liver damage in CLI, and the intervention of Nrf2/HO-1 signaling possesses a potential translational value in the clinical treatment of cholestatic liver disease. The gene discussed is HMOX1; the disease is Cholestatic liver disease.